(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.35%) $78.38
(0.33%) $2.15
(0.48%) $2 319.70
(1.67%) $27.14
(-0.23%) $963.05
(0.01%) $0.929
(-0.11%) $10.86
(0.01%) $0.797
(0.00%) $91.45
2 days till quarter result
(bmo 2024-05-08)
Expected move: +/- 8.17%
@ $4.90
发出时间: 15 Feb 2024 @ 04:50
回报率: -37.28%
上一信号: Feb 15 - 02:56
上一信号:
回报率: 2.30 %
Live Chart Being Loaded With Signals
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer...
Stats | |
---|---|
今日成交量 | 1.34M |
平均成交量 | 2.26M |
市值 | 524.12M |
EPS | $0 ( 2024-05-01 ) |
下一个收益日期 | ( $-0.390 ) 2024-05-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.470 |
ATR14 | $0.00600 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-22 | Moore Timothy L. | Sell | 17 360 | Common Stock |
2024-03-14 | Chang David D | Sell | 53 393 | Common Stock |
2024-01-30 | Parker Geoffrey M. | Buy | 190 | Common Stock |
2024-01-25 | Moore Timothy L. | Buy | 341 515 | Stock Option (Right to buy) |
2024-01-25 | Moore Timothy L. | Buy | 96 600 | Common Stock |
INSIDER POWER |
---|
93.40 |
Last 94 transactions |
Buy: 32 219 312 | Sell: 32 079 170 |
音量 相关性
Allogene Therapeutics Inc 相关性 - 货币/商品
Allogene Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $95 000.00 |
毛利润: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2023 |
营收: | $95 000.00 |
毛利润: | $-242.82M (-255 598.95 %) |
EPS: | $-2.09 |
FY | 2022 |
营收: | $243 000 |
毛利润: | $-16.49M (-6 783.95 %) |
EPS: | $-2.30 |
FY | 2021 |
营收: | $38.49M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.14 |
Financial Reports:
No articles found.
Allogene Therapeutics Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。